The first round of funding to states is expected to arrive in May, with additional funds available by July. (Photo: Shutterstock)
Johnson & Johnson's Janssen Pharmaceuticals and three other drug companies have agreed to move forward on a $26 billion global opioid settlement, the second largest multistate agreement in U.S. history.
The deal, announced July 21, was contingent on a certain percentage of states, cities and counties participating. Today was the deadline for the defendants to decide whether the participation rate was enough to resolve the vast majority of more than 4,000 opioid claims brought by governments across the country.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Amanda Bronstad
Amanda Bronstad is the ALM staff reporter covering class actions and mass torts nationwide. She writes the email dispatch Law.com Class Actions: Critical Mass. She is based in Los Angeles.
